2019

News
Share this article
29 June 2017

>100 public qualified hits

Every year since 2015, around 50,000 public compounds, designed and synthesized by the European Lead Factory chemistry partners, have been added to the ELF screening collection the Joint European Compound Library.

News
Share this article
19 June 2017

ChemPass receives the highest monetary award from the European Lead Factory

Any European researcher can submit a design proposal of a chemical library that can be synthesised by the European Lead Factory and can subsequently be incorporated in the Joint European Compound Library (JECL). The project Library Design Committee rates the designs on six scientific criteria and determines the technical maturity level of the proposals. Budapest-based ChemPass ltd rose to the challenge and recently received the highest monetary award of 5.000 Euros for their library design proposal.

News
Share this article
24 May 2017

French biotech receives Qualified Hit List

The French biotech company CELLIPSE has taken the next step towards novel treatments for leukaemia patients thanks to the European Lead Factory.

News
Share this article
28 April 2017

Hitting the targets – Inspiring Stakeholder Meeting

On the 25-26 April the European Lead Factory (ELF) Stakeholder Meeting and 5th General Assembly took place close to Heathrow/Windsor, UK. With an exciting agenda focussing on four years of successful collaboration, the impact of the European Lead Factory and the future of drug discovery, the meeting was considered a great success by all participants.

News
Share this article
15 March 2017

Over 1,000 library proposals submitted to ELF

The European Lead Factory recently reached the milestone of having received over 1,000 library proposals for consideration.  These proposals have been considered by its Library Selection Committee, leading to the approval of 627 library designs for synthetic validation.

News
Share this article
08 March 2017

Virtual biotech company launched to battle Parkinson’s

In a world-first type of collaboration, Parkinson’s UK and the University of Sheffield have launched a joint venture biotech company, Keapstone Therapeutics. Parkinson’s UK has allocated 1 million GBP over the next sixteen months to further develop compounds that boost the internal cellular defence mechanisms against oxidative stress. These compounds were discovered by IMI’s European Lead Factory.

News
Share this article
04 February 2017

World Cancer Day 2017

We can. I can. That is the message that is spread during World Cancer Day, on 4 February. How can you – as a collective or as an individual – take action to reduce the global burden of cancer? The European Lead Factory currently has 34 programmes that focus on various targets related to cancer. In these programmes innovative approaches are used to find starting points for new drugs to fight this disease. 

News
Share this article
23 January 2017

Committed to strengthening the antibiotic arsenal

The European Lead Factory (ELF) is boosting the discovery of new drugs by making high throughput screening and a quality compound library available to academia and biotech’s. To be eligible, the proposed project has to meet certain conditions. For example, the project should be considered as innovative and it should be possible to optimize the associated assay for high throughput screening.

News
Share this article
19 January 2017

PDE4NPD and the European Lead Factory team up: parasite enzyme up for ultra-HTS against 450,000 compounds

With help of the European Lead Factory, the Phosphodiesterase Inhibitors for Neglected Parasitic Diseases (PDE4NPD) project takes the next step towards developing novel drugs against kinetoplastid parasites such as Trypanosoma brucei, the causative parasite of African sleeping sickness, and Trypanosoma cruzi, causing Chagas disease. Together, PDE4NPD and the EU Lead Factory will screen 450,000 compounds for their potential to inhibit one of the parasite PDEs the project has validated. 

News
Share this article
19 January 2017

A blueprint for public-private partnerships in early drug discovery

A recent review in Frontier in Medicine describes the outcomes and learnings of the first 3,5 years of European Lead Factory (ELF) operations. It gives an overview of the unique characteristics and results of the programme: ‘ELF enables breakthroughs in areas with unmet medical and societal needs, where no individual entity would be able to create a comparable impact in such a short time’.

Pages